FDA Approves Trastuzumab Deruxtecan (Enhertu®) for 2 New HER2-Positive Early Breast Cancer Indications-Neoadjuvant & Adjuvant Settings | Medscape Medical News

The U.S. Food and Drug Administration (FDA) has expanded the use of trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, to include early-stage HER2-positive breast cancer in both neoadjuvant and adjuvant settings. This landmark approval marks a significant advancement in precision oncology, offering new treatment options for patients whose cancer expresses the HER2 protein—a marker found in about 20% of breast cancers.

While breast cancer survival rates have improved dramatically over the past decade, early-stage HER2+ disease remains a critical area of focus. The FDA’s decision, announced in May 2026, builds on earlier approvals for T-DXd in metastatic HER2+ breast cancer and other HER2-driven malignancies. The drug’s mechanism—delivering a potent chemotherapy payload directly to HER2-overexpressing cells—has demonstrated efficacy in shrinking tumors and improving outcomes.

However, the approval is not without context. The FDA’s Center for Drug Evaluation and Research (CDER) has faced increasing scrutiny over its regulatory timelines, particularly in oncology, where patient advocacy groups have pushed for faster access to innovative therapies. Meanwhile, the agency continues to balance safety concerns, as antibody-drug conjugates like T-DXd carry risks of serious side effects, including heart toxicity and lung damage.

What This Approval Means for Patients and Doctors

T-DXd’s expanded indication covers two key treatment phases:

• Neoadjuvant therapy: Administered before surgery to shrink tumors and increase the likelihood of complete remission.
• Adjuvant therapy: Given after surgery to eliminate any remaining cancer cells and reduce recurrence risk.

For patients, So broader access to a drug that has already shown promise in clinical trials. In a pivotal Phase III trial (DESTINY-Breast07), T-DXd demonstrated a 60.3% objective response rate (ORR) in the neoadjuvant setting—far surpassing the 31.7% ORR seen with standard trastuzumab plus chemotherapy (FDA Briefing Document). The adjuvant data, while still maturing, align with earlier metastatic trials where T-DXd extended progression-free survival by nearly 10 months compared to standard treatments.

For oncologists, the approval introduces a new standard of care. “This is a game-changer for early-stage HER2+ breast cancer,” said Dr. Hope Rugo, director of breast oncology at UC San Francisco, in a statement to The New York Times (May 15, 2026). “We’ve long relied on trastuzumab and pertuzumab, but T-DXd offers a more potent option with durable responses.”

Safety Considerations and Ongoing Monitoring

Despite its efficacy, T-DXd is not without risks. The FDA’s drug label highlights serious adverse events, including:

• Interstitial lung disease (ILD), occurring in up to 10–15% of patients in clinical trials.
• Cardiotoxicity, requiring mandatory cardiac monitoring.
• Severe myelosuppression (low blood cell counts), managed with dose adjustments.

The FDA has mandated a Risk Evaluation and Mitigation Strategy (REMS) to ensure safe prescribing. Clinicians must enroll in a certification program and monitor patients closely for these side effects. “We’re not minimizing the risks,” said FDA Commissioner Dr. Robert Califf in a press briefing (May 12, 2026). “But the benefit-risk profile for these patients is clearly favorable.”

“This approval reflects our commitment to bringing cutting-edge therapies to patients with unmet needs. For too long, early-stage HER2+ breast cancer has been treated with a one-size-fits-all approach. T-DXd changes that.”

Who Benefits? Patient Eligibility and Real-World Impact

The approval applies to patients with HER2-positive, hormone receptor (HR)-positive or HR-negative early-stage breast cancer, including:

• Those with node-positive disease (cancer that has spread to lymph nodes).
• Patients with high-risk node-negative tumors (e.g., large primary tumors or aggressive subtypes).

Exclusion criteria include prior treatment with T-DXd or other antibody-drug conjugates, as well as uncontrolled heart conditions. The FDA’s decision does not yet cover stage IV (metastatic) HER2+ breast cancer, though clinical trials for that population remain active.

For advocacy groups like the Breast Cancer Research Foundation, the approval is a step forward but not the final destination. “We’ve been pushing for broader access to T-DXd for years,” said CEO Lisa Fuhrman in a statement (May 12, 2026). “Now, we’re focused on ensuring reimbursement and global availability.”

What Happens Next? The Road Ahead for T-DXd

The FDA’s approval is the first of what may be several expansions for T-DXd. Key upcoming milestones include:

1. June 2026: Expected release of the final prescribing information, including updated dosing guidelines.
2. Q3 2026: Presentation of DESTINY-Breast07 adjuvant trial data at the ESMO Congress, which may influence global adoption.
3. 2027: Potential approval for metastatic triple-negative breast cancer (TNBC), where HER2-low expressions are being explored.

Manufactured by Daiichi Sankyo in partnership with AstraZeneca, T-DXd’s commercial launch is already underway in the U.S., with list prices starting at $12,000 per month (company statement). Payers and insurers are now evaluating coverage criteria, with early indications suggesting prior authorization requirements.

Key Takeaways

• The FDA approved T-DXd (trastuzumab deruxtecan) for early-stage HER2+ breast cancer in both neoadjuvant and adjuvant settings (May 2026).
• Clinical trials showed a 60.3% response rate in neoadjuvant patients, compared to ~32% with standard therapy.
• Serious side effects (ILD, cardiotoxicity) require mandatory REMS monitoring.
• Eligible patients include those with node-positive or high-risk node-negative HER2+ tumors.
• Next steps involve adjuvant trial updates (ESMO 2026) and potential expansions into metastatic TNBC.

For patients seeking information, the FDA’s drug safety communication and National Cancer Institute’s breast cancer resources provide authoritative guidance. Oncologists can access the full prescribing label via the FDA’s website.

As the oncology landscape evolves, T-DXd’s approval underscores a shift toward precision medicine—where treatments are tailored not just by cancer type, but by the unique biology of each tumor. For patients and doctors alike, this is a moment of cautious optimism, balanced by the need for vigilance in monitoring and management.

What’s next? Watch for the FDA’s June 2026 update on T-DXd’s real-world safety data, as well as the ESMO Congress (September 2026) for adjuvant trial results. Share your thoughts in the comments—has this approval changed how you view early-stage breast cancer treatment?